Promus Capital LLC Buys Shares of 1,273 AstraZeneca PLC (NASDAQ:AZN)

Promus Capital LLC purchased a new stake in shares of AstraZeneca PLC (NASDAQ:AZN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 1,273 shares of the company’s stock, valued at approximately $83,000.

A number of other hedge funds also recently made changes to their positions in the business. Crumly & Associates Inc. raised its holdings in shares of AstraZeneca by 2.2% during the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after buying an additional 143 shares during the last quarter. Diversify Wealth Management LLC raised its holdings in shares of AstraZeneca by 3.6% during the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after buying an additional 153 shares during the last quarter. Veery Capital LLC raised its holdings in AstraZeneca by 4.7% during the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock worth $230,000 after purchasing an additional 157 shares in the last quarter. Harbour Investments Inc. raised its holdings in AstraZeneca by 1.9% during the third quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock worth $686,000 after purchasing an additional 160 shares in the last quarter. Finally, Rehmann Capital Advisory Group lifted its position in AstraZeneca by 1.8% in the third quarter. Rehmann Capital Advisory Group now owns 10,027 shares of the company’s stock worth $788,000 after purchasing an additional 175 shares during the period. Institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. UBS Group upgraded AstraZeneca from a “neutral” rating to a “buy” rating in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Finally, Morgan Stanley assumed coverage on AstraZeneca in a report on Wednesday, February 12th. They issued an “overweight” rating for the company. One research analyst has rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Up 0.9 %

Shares of NASDAQ AZN opened at $77.96 on Thursday. AstraZeneca PLC has a 12 month low of $62.75 and a 12 month high of $87.68. The company has a market cap of $241.77 billion, a price-to-earnings ratio of 34.50, a P/E/G ratio of 1.42 and a beta of 0.41. The company has a quick ratio of 0.74, a current ratio of 0.93 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $70.39 and a 200-day simple moving average of $72.84.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing the consensus estimate of $1.10 by ($0.05). AstraZeneca had a net margin of 13.01% and a return on equity of 32.23%. Sell-side analysts predict that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be issued a dividend of $1.03 per share. This represents a dividend yield of 2%. This is an increase from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. AstraZeneca’s dividend payout ratio is currently 91.15%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.